Advertisement

Sarcomatoid Urothelial Carcinoma: A Population-Based Study of Clinicopathologic Characteristics and Survival Outcomes

Published:December 24, 2021DOI:https://doi.org/10.1016/j.clgc.2021.12.015

      Abstract

      Introduction

      Sarcomatoid urothelial carcinoma (SUC) is a rare and aggressive variant of bladder cancer with limited data regarding epidemiology and survival. In this study, we explored clinicopathologic factors and oncologic outcomes of patients with SUC derived from Survival, Epidemiology and End Results (SEER) database, in comparison to conventional UC (CUC).

      Materials and Methods

      SEER database was searched for patients with invasive (≥T1) SUC or CUC using the topography codes C67.0 to C67.9 for bladder cancer and the morphologic codes 8120/8122 for CUC/SUC respectively. Demographic/clinicopathologic/treatment/survival data were extracted. Disease-specific survival (DSS) was estimated with the Kaplan-Meier method. Chi-squared tests were used for comparative analysis and Cox proportional hazards model for identifying clinical covariates associated with DSS.

      Results

      A total of 569 patients with SUC and 37,740 with CUC were identified. Overall, there was a male predominant population in both cohorts, although a higher proportion of women were noted in the SUC cohort (32 vs. 25%). Patients with SUC had significantly higher incidence of non-bladder confined disease (T3/4, 37% vs. 22%) and nodal invasion (18% vs. 12%) in comparison to those with CUC (all P < .05). Median DSS was 16 months (95% CI: 12.4-19.6) in the SUC vs. 82 months (95% CI; 75.9-88.1) in the CUC cohort. Presence of SUC histology was independently associated with shorter DSS in the multivariate analysis, when adjusted for other significant clinicopathologic factors.

      Conclusion

      SUC was associated with advanced stage and shorter DSS compared to CUC. Further studies are needed to better understand biological underpinnings behind its aggressive behavior and the role of novel systemic treatments.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Humphrey PA
        • Moch H
        • Cubilla AL
        • Ulbright TM
        • Reuter VE.
        The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours.
        Eur Urol. 2016; 70: 106-119
        • Cheng L
        • Zhang S
        • Alexander R
        • et al.
        Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation.
        Am J Surg Pathol. 2011; 35: e34-e46
        • Armstrong AB
        • Wang M
        • Eble JN
        • et al.
        TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder.
        Mod Pathol. 2009; 22: 113-118
        • Sui W
        • Matulay JT
        • Onyeji IC
        • et al.
        Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer.
        World J Urol. 2017; 35: 1055-1061
        • Diamantopoulos LN
        • Sekar RR
        • Khaki AR
        • et al.
        Sarcomatoid urothelial carcinoma (SUC): a single-institution experience of oncologic outcomes and recurrence patterns.
        J Clin Oncol. 2020; 38 (465): 465
        • Paner GP
        • Stadler WM
        • Hansel DE
        • Montironi R
        • Lin DW
        • Amin MB.
        Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers.
        Eur Urol. 2018; 73: 560-569
        • Heinze G
        • Wallisch C
        • Dunkler D.
        Variable selection - A review and recommendations for the practicing statistician.
        Biom J. 2018; 60: 431-449
        • Wright JL
        • Black PC
        • Brown GA
        • et al.
        Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.
        J Urol. 2007; 178 (discussion 2307): 2302-2306
        • Wang J
        • Wang FW
        • Lagrange CA
        • Hemstreet Iii GP
        • Kessinger A
        Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases.
        Sarcoma. 2010; (2010)
        • Vetterlein MW
        • Wankowicz SAM
        • Seisen T
        • et al.
        Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
        Cancer. 2017; 123: 4346-4355
        • Fatima N
        • Canter DJ
        • Carthon BC
        • et al.
        Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases.
        Can J Urol. 2015; 22: 7783-7787
        • Sanfrancesco J
        • McKenney JK
        • Leivo MZ
        • Gupta S
        • Elson P
        • Hansel DE.
        Sarcomatoid urothelial carcinoma of the bladder: analysis of 28 cases with emphasis on clinicopathologic features and markers of epithelial-to-mesenchymal transition.
        Arch Pathol Lab Med. 2016; 140: 543-551
        • Wang J
        • Gillaspie C
        • Kunadharaju R
        • Talmon GA
        • Enke C.
        Sarcomatoid urothelial carcinoma: a single cancer center experience.
        World J Oncol. 2011; 2: 175-180
        • Sabaté Arroyo XA
        • Rodrigo Lara H
        • Carrillo García P
        • Brugarolas Rosselló J
        • Pizá Reus P
        Sarcomatoid urothelial bladder carcinoma in adults: Histology, symptomatology, treatments and survival.
        Actas Urol Esp. 2019; 43: 106-110
        • Başeskioglu B
        • Duman BB
        • Kara IO
        • Can C
        • Yildirim M
        • Açikalin M.
        Early detection and gemcitabine/cisplatin combination positively effect survival in sarcomatoid carcinoma of the urinary bladder.
        Asian Pac J Cancer Prev. 2012; 13: 5729-5733
        • Genitsch V
        • Kollár A
        • Vandekerkhove G
        • et al.
        Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
        Urol Oncol. 2019; 37: 826-836
        • Guo CC
        • Majewski T
        • Zhang L
        • et al.
        Dysregulation of EMT drives the progression to clinically aggressive sarcomatoid bladder cancer.
        Cell Rep. 2019; 27 (e1784): 1781-1793
        • Miller NJ
        • Khaki AR
        • Diamantopoulos LN
        • et al.
        Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study.
        J Urol. 2020; 204: 63-70